Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Kurebayashi J, Shiba E, Toyama T, Matsumoto H, Okazaki M, Nomizu T, Ohtake T, Fujii T, Ohashi Y. Kurebayashi J, et al. Among authors: ohashi y. Breast Cancer. 2021 May;28(3):684-697. doi: 10.1007/s12282-020-01205-w. Epub 2021 Feb 27. Breast Cancer. 2021. PMID: 33638810 Free PMC article. Clinical Trial.
A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Shiba E, Yamashita H, Kurebayashi J, Noguchi S, Iwase H, Ohashi Y, Sasai K, Fujimoto T. Shiba E, et al. Among authors: ohashi y. Breast Cancer. 2016 May;23(3):499-509. doi: 10.1007/s12282-015-0593-z. Epub 2015 Feb 6. Breast Cancer. 2016. PMID: 25655898 Free PMC article. Clinical Trial.
Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial.
Ohashi Y, Shiba E, Yamashita H, Kurebayashi J, Noguchi S, Iwase H, Yoshida M, Fujimoto T. Ohashi Y, et al. Support Care Cancer. 2018 Mar;26(3):933-945. doi: 10.1007/s00520-017-3914-2. Epub 2017 Oct 24. Support Care Cancer. 2018. PMID: 29063390 Free PMC article. Clinical Trial.
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group].
Abe R, Tominaga T, Nomizu T, Nomura Y, Takashima S, Koyama H, Sano M, Tohge T, Ueo H, Ikeda S, Ohashi Y; CGS20267 Study Group. Abe R, et al. Among authors: ohashi y. Gan To Kagaku Ryoho. 2002 May;29(5):729-40. Gan To Kagaku Ryoho. 2002. PMID: 12040677 Clinical Trial. Japanese.
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group].
Kimijima I, Tominaga T, Nomizu T, Nomura Y, Takashima S, Koyama H, Sano M, Tohge T, Ueo H, Ikeda S, Ohashi Y; CGS20267 Study Group. Kimijima I, et al. Among authors: ohashi y. Gan To Kagaku Ryoho. 2002 May;29(5):741-9. Gan To Kagaku Ryoho. 2002. PMID: 12040678 Clinical Trial. Japanese.
Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
Saeki T, Nomizu T, Toi M, Ito Y, Noguchi S, Kobayashi T, Asaga T, Minami H, Yamamoto N, Aogi K, Ikeda T, Ohashi Y, Sato W, Tsuruo T. Saeki T, et al. Among authors: ohashi y. J Clin Oncol. 2007 Feb 1;25(4):411-7. doi: 10.1200/JCO.2006.08.1646. Epub 2006 Dec 18. J Clin Oncol. 2007. PMID: 17179098 Clinical Trial.
A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study.
Takashima T, Hara F, Iwamoto T, Uemura Y, Ohsumi S, Yotsumoto D, Hozumi Y, Watanabe T, Saito T, Watanabe KI, Tsurutani J, Toyama T, Akabane H, Nishimura R, Taira N, Ohashi Y, Mukai H. Takashima T, et al. Among authors: ohashi y. Clin Breast Cancer. 2021 Oct;21(5):450-457. doi: 10.1016/j.clbc.2021.01.018. Epub 2021 Feb 1. Clin Breast Cancer. 2021. PMID: 33685834
2,164 results